303 related articles for article (PubMed ID: 22161221)
1. BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.
Graf JF; Scholz BJ; Zavodszky MI
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):37-54. PubMed ID: 22161221
[TBL] [Abstract][Full Text] [Related]
2. [Progress in methodology of establishing physiologically based pharmacokinetic models].
Jin YW; Ma YM
Yao Xue Xue Bao; 2014 Jan; 49(1):16-22. PubMed ID: 24783500
[TBL] [Abstract][Full Text] [Related]
3. Physiologically based pharmacokinetics (PBPK).
Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
[TBL] [Abstract][Full Text] [Related]
4. Modelling and PBPK simulation in drug discovery.
Jones HM; Gardner IB; Watson KJ
AAPS J; 2009 Mar; 11(1):155-66. PubMed ID: 19280352
[TBL] [Abstract][Full Text] [Related]
5. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
Peters SA; Ungell AL; Dolgos H
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647
[TBL] [Abstract][Full Text] [Related]
6. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.
Jones HM; Mayawala K; Poulin P
AAPS J; 2013 Apr; 15(2):377-87. PubMed ID: 23269526
[TBL] [Abstract][Full Text] [Related]
7. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
Poulin P
J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
[TBL] [Abstract][Full Text] [Related]
8. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.
Dallmann A; Ince I; Solodenko J; Meyer M; Willmann S; Eissing T; Hempel G
Clin Pharmacokinet; 2017 Dec; 56(12):1525-1541. PubMed ID: 28391404
[TBL] [Abstract][Full Text] [Related]
10. A whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics.
Oliver RE; Jones AF; Rowland M
J Pharmacokinet Pharmacodyn; 2001 Feb; 28(1):27-55. PubMed ID: 11253612
[TBL] [Abstract][Full Text] [Related]
11. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
[TBL] [Abstract][Full Text] [Related]
12. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
Johnson TN; Rostami-Hodjegan A
Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
Bouzom F; Ball K; Perdaems N; Walther B
Biopharm Drug Dispos; 2012 Mar; 33(2):55-71. PubMed ID: 22228149
[TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.
Sager JE; Yu J; Ragueneau-Majlessi I; Isoherranen N
Drug Metab Dispos; 2015 Nov; 43(11):1823-37. PubMed ID: 26296709
[TBL] [Abstract][Full Text] [Related]
15. Utility of a single adjusting compartment: a novel methodology for whole body physiologically-based pharmacokinetic modelling.
Ando H; Izawa S; Hori W; Nakagawa I
Theor Biol Med Model; 2008 Aug; 5():19. PubMed ID: 18687151
[TBL] [Abstract][Full Text] [Related]
16.
Kamiya Y; Handa K; Miura T; Yanagi M; Shigeta K; Hina S; Shimizu M; Kitajima M; Shono F; Funatsu K; Yamazaki H
Chem Res Toxicol; 2021 Feb; 34(2):507-513. PubMed ID: 33433197
[TBL] [Abstract][Full Text] [Related]
17. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
18. Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.
Jones HM; Gardner IB; Collard WT; Stanley PJ; Oxley P; Hosea NA; Plowchalk D; Gernhardt S; Lin J; Dickins M; Rahavendran SR; Jones BC; Watson KJ; Pertinez H; Kumar V; Cole S
Clin Pharmacokinet; 2011 May; 50(5):331-47. PubMed ID: 21456633
[TBL] [Abstract][Full Text] [Related]
19. Physiologically Based Pharmacokinetic Models Predicting Renal and Hepatic Concentrations of Industrial Chemicals after Virtual Oral Doses in Rats.
Kamiya Y; Otsuka S; Miura T; Yoshizawa M; Nakano A; Iwasaki M; Kobayashi Y; Shimizu M; Kitajima M; Shono F; Funatsu K; Yamazaki H
Chem Res Toxicol; 2020 Jul; 33(7):1736-1751. PubMed ID: 32500706
[TBL] [Abstract][Full Text] [Related]
20. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
Peters SA
Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
